Sanofi Inventory Turnover Ratio 2010-2023 | SNY
Current and historical inventory turnover ratio for Sanofi (SNY) from 2010 to 2023. Inventory turnover ratio can be defined as a ratio showing how many times a company's inventory is sold and replaced over a period. Sanofi inventory turnover ratio for the three months ending December 31, 2023 was 0.42.
Sanofi Inventory Turnover Ratio Historical Data |
Date |
|
|
|
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Large Cap Pharmaceutical |
$117.905B |
$46.611B |
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|